CA3212292A1 - Purine derivatives as anticancer agents - Google Patents

Purine derivatives as anticancer agents Download PDF

Info

Publication number
CA3212292A1
CA3212292A1 CA3212292A CA3212292A CA3212292A1 CA 3212292 A1 CA3212292 A1 CA 3212292A1 CA 3212292 A CA3212292 A CA 3212292A CA 3212292 A CA3212292 A CA 3212292A CA 3212292 A1 CA3212292 A1 CA 3212292A1
Authority
CA
Canada
Prior art keywords
alkyl
cancer
cycloalkyl
compound
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3212292A
Other languages
English (en)
French (fr)
Inventor
Scott Throner
Daniel Jonsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Tango Therapeutics Inc
Original Assignee
Medivir AB
Tango Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir AB, Tango Therapeutics Inc filed Critical Medivir AB
Publication of CA3212292A1 publication Critical patent/CA3212292A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3212292A 2021-03-17 2022-03-17 Purine derivatives as anticancer agents Pending CA3212292A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162460P 2021-03-17 2021-03-17
US63/162,460 2021-03-17
PCT/US2022/020700 WO2022197892A1 (en) 2021-03-17 2022-03-17 Purine derivatives as anticancer agents

Publications (1)

Publication Number Publication Date
CA3212292A1 true CA3212292A1 (en) 2022-09-22

Family

ID=81327909

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3212292A Pending CA3212292A1 (en) 2021-03-17 2022-03-17 Purine derivatives as anticancer agents

Country Status (11)

Country Link
US (1) US20240059689A1 (https=)
EP (1) EP4308566A1 (https=)
JP (1) JP2024511996A (https=)
KR (1) KR20240006509A (https=)
CN (1) CN117425656A (https=)
AU (1) AU2022238886A1 (https=)
BR (1) BR112023018799A2 (https=)
CA (1) CA3212292A1 (https=)
IL (1) IL305991A (https=)
MX (1) MX2023010909A (https=)
WO (1) WO2022197892A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312642A (en) 2021-11-12 2024-07-01 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
EP4430049A4 (en) * 2021-11-12 2025-12-17 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof
TW202509030A (zh) 2023-05-08 2025-03-01 美商譚格醫療公司 化合物及使用方法
WO2024233665A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
CN117024253A (zh) * 2023-08-14 2023-11-10 江西阿尔法高科药业有限公司 一种药用级麝香草酚特定杂质的制备方法
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
TW202539659A (zh) 2024-01-10 2025-10-16 美商維瑞斯治療股份有限公司 Ｄｎａ損傷修復途徑的新穎抑制劑
WO2025256544A1 (zh) * 2024-06-11 2025-12-18 福建盛迪医药有限公司 一种1-氨烷基修饰的呋喃核糖衍生物的制备方法
CN119751316A (zh) * 2024-12-20 2025-04-04 江南大学 一种1-苯基三氟甲基n-（氟磺酰基）氨基甲酸酯化合物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
JP2011236198A (ja) * 2010-04-13 2011-11-24 Daiichi Sankyo Co Ltd モルホリノプリン誘導体
CN108473495B (zh) * 2015-11-20 2022-04-12 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
US11485736B2 (en) * 2018-12-20 2022-11-01 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors

Also Published As

Publication number Publication date
KR20240006509A (ko) 2024-01-15
IL305991A (en) 2023-11-01
CN117425656A (zh) 2024-01-19
MX2023010909A (es) 2024-02-13
JP2024511996A (ja) 2024-03-18
AU2022238886A1 (en) 2023-09-14
WO2022197892A1 (en) 2022-09-22
EP4308566A1 (en) 2024-01-24
BR112023018799A2 (pt) 2023-12-12
US20240059689A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
CA3212292A1 (en) Purine derivatives as anticancer agents
EP4291559A1 (en) Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
US12403137B2 (en) Compounds and methods of use
US20230113778A1 (en) Compounds and methods of use
AU2017289158C1 (en) 4,6-diaminoquinazolines as Cot modulators and methods of use thereof
AU2017363307B2 (en) Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
US11986471B2 (en) Compounds and methods of use
WO2024233605A1 (en) Compounds and their use against cancer
CA2918910A1 (en) Inhibitors of transcription factors and uses thereof
WO2023146991A1 (en) Compounds and methods of use
CA3142478A1 (en) Cot modulators and methods of use thereof
JP2025503969A (ja) 化合物及び使用方法
US20250171432A1 (en) Compounds and methods of use
WO2023146990A1 (en) Compounds and methods of use
JP2025539828A (ja) Ｒｉｐｋ２の阻害剤及びその医学的使用
JP2025501503A (ja) Ｎ－（６－アミノ－５－メチルピリジン－３－イル）－２－（ベンゾ［ｄ］チアゾール－５－イル）－５－メチルピペリジン－１－イル）－２－オキソアセトアミドの結晶形態、医薬組成物、及びその使用方法
WO2024233665A1 (en) Compounds and their use against cancer
JP2026506763A (ja) サイクリン依存性キナーゼ分解剤およびその使用方法
WO2026073277A1 (en) Substituted piperidine-diones inactivating hbs1l
WO2026090589A1 (en) Heterocyclic hbs1l degraders
CN118715207A (zh) 化合物和使用方法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307